Analysts’ Weekly Ratings Updates for Summit Therapeutics (SMMT)

Several analysts have recently updated their ratings and price targets for Summit Therapeutics (NASDAQ: SMMT):

• 8/26/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Guggenheim.
• 8/26/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 8/25/2026 – Summit Therapeutics was given a new $11.90 price target by Summit Redstone.
• 8/25/2026 – Summit Therapeutics was upgraded by Sanford C. Bernstein from “underperform” to “market perform”. They now have a $11.90 price target on the stock, up from $9.80.
• 8/18/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 8/12/2026 – Summit Therapeutics was upgraded by Leerink Partners from “underperform” to “market perform”. They now have a $13.00 price target on the stock, up from $12.00.
• 8/6/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/24/2026 – Summit Therapeutics was given a new $15.00 price target by Jefferies Financial Group Inc..
• 7/24/2026 – Summit Therapeutics had its price target lowered by Stifel Nicolaus from $45.00 to $38.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Summit Therapeutics had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/18/2026 – Summit Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Summit Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/4/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Activity at Summit Therapeutics

In related news, CFO Manmeet Singh Soni acquired 50,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were purchased at an average cost of $14.45 per share, with a total value of $722,500.00. Following the completion of the acquisition, the chief financial officer directly owned 3,123,603 shares of the company’s stock, valued at $45,136,063.35. This represents a 1.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mahkam Zanganeh acquired 3,810,000 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was purchased at an average cost of $13.12 per share, for a total transaction of $49,987,200.00. Following the completion of the acquisition, the chief executive officer directly owned 573,883,879 shares of the company’s stock, valued at approximately $7,529,356,492.48. This trade represents a 0.67% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 7,870,000 shares of company stock valued at $103,616,900 over the last quarter. 83.50% of the stock is owned by corporate insiders.

Summit Therapeutics plc is a clinical?stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life?threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.